<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065906</url>
  </required_header>
  <id_info>
    <org_study_id>KY20192044-F-1</org_study_id>
    <nct_id>NCT04065906</nct_id>
  </id_info>
  <brief_title>Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder</brief_title>
  <official_title>Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the clinical efficacy and mechanism of functional near-infrared spectroscopy
      imaging neurofeedback therapy for attention deficit and hyperactivity disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, a parallel controlled study will be conducted to recruit 60 patients with
      ADHD, 30 patients in the fNIRS group and 30 patients in the drug group. At the same time, 30
      healthy controls will be recruited. 6 weeks, 12 sessions of NIRS feedback will be given for
      participants in NIRS group and healthy controls. 6 weeks of first or second line medication
      will be given for participants of drug group. Magnetic resonance imaging will be performed at
      baseline for all participants. SNAP IV, PSQ, CGI will be evaluated at baseline, week 3, week
      6 and week 8 for ADHD participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SNAP-IV</measure>
    <time_frame>Baseline, week 3, week 6, week 8</time_frame>
    <description>Change in SNAP-IV(Swanson, Nolan, and Pelham-IV rating scales) score between groups over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CGI</measure>
    <time_frame>Baseline, week 3, week 6, week 8</time_frame>
    <description>Change in CGI (Clinical Global Impression Scale) score between groups over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSQ</measure>
    <time_frame>Baseline, week 3, week 6, week 8</time_frame>
    <description>Change in PSQ(Parent Symptom Questionnaire) score between groups over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRS</measure>
    <time_frame>Baseline, week 3, week 6, week 8</time_frame>
    <description>Change in TRS (Conners' Teacher Rating Scale, TRS )score between groups over time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Neurofeedback</condition>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>NIRS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy children, 12 sessions of NIRS feedback, for two sessions per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>NIRS neurofeedback</intervention_name>
    <description>Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>NIRS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate or Tomoxetine</intervention_name>
    <description>Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD</description>
    <arm_group_label>Drug group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For ADHD patients:

        Inclusion Criteria:

          -  diagnosed with TD, according to the American Diagnostic and Statistical Manual of
             Mental Disorders, 5th Edition (DSM-5);

          -  aged 6-12;

          -  right handed;

        Exclusion Criteria:

          -  full-scale intelligence quotient below 80(measured by Wechsler Intelligence Scale for
             Childrenï¼ŒWISC)

          -  medical or neurological disorders, psychiatric disorders other than oppositional
             defiant disorder

          -  current participation in a psychotherapeutic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenjun Wu, master</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital, The Air Force Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huaning Wang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital, The Air Force Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi Zhang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xidian University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenjun Wu, master</last_name>
    <phone>+86 02984771141</phone>
    <email>wenjun104@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huaning Wang, doctor</last_name>
    <phone>+86 02984771141</phone>
    <email>xskzhu@fmmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry, Xijing Hospital, The Air Force Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjun Wu, master</last_name>
      <phone>+86 02984771141</phone>
      <email>wenjun104@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Huaning Wang, doctor</last_name>
      <phone>+86 02984771141</phone>
      <email>xskzhu@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Inoue Y, Sakihara K, Gunji A, Ozawa H, Kimiya S, Shinoda H, Kaga M, Inagaki M. Reduced prefrontal hemodynamic response in children with ADHD during the Go/NoGo task: a NIRS study. Neuroreport. 2012 Jan 25;23(2):55-60. doi: 10.1097/WNR.0b013e32834e664c.</citation>
    <PMID>22146580</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer K, Wyckoff SN, Fallgatter AJ, Ehlis AC, Strehl U. Neurofeedback as a nonpharmacological treatment for adults with attention-deficit/hyperactivity disorder (ADHD): study protocol for a randomized controlled trial. Trials. 2015 Apr 18;16:174. doi: 10.1186/s13063-015-0683-4.</citation>
    <PMID>25928870</PMID>
  </results_reference>
  <results_reference>
    <citation>Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, Santosh P, Simonoff E, Stevenson J, Stringaris A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):444-55. doi: 10.1016/j.jaac.2016.03.007. Epub 2016 Apr 1. Review.</citation>
    <PMID>27238063</PMID>
  </results_reference>
  <results_reference>
    <citation>Hudak J, Rosenbaum D, Barth B, Fallgatter AJ, Ehlis AC. Functionally disconnected: A look at how study design influences neurofeedback data and mechanisms in attention-deficit/hyperactivity disorder. PLoS One. 2018 Aug 10;13(8):e0200931. doi: 10.1371/journal.pone.0200931. eCollection 2018.</citation>
    <PMID>30096196</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Wu Wenjun-1</investigator_full_name>
    <investigator_title>Department of Psychiatry, Xijing Hospital, The Air Force Medical University</investigator_title>
  </responsible_party>
  <keyword>NIRS</keyword>
  <keyword>fNIRS</keyword>
  <keyword>neurofeedback</keyword>
  <keyword>attention deficit hyperactivity disorder (ADHD)</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

